Literature DB >> 9241550

Cyproterone acetate monotherapy in advanced prostatic carcinoma.

O Kayigil1, O Atahan, A Metin.   

Abstract

Cyproterone acetate was given as monotherapy to 18 patients with advanced prostatic carcinoma at a weekly dose of 300 mg. Progression was observed in all of the patients; median time to progression was 35 months and median survival time was 48 months. Partial response, stabilization, progression and exitus rates by years also showed favourable results, as compared with other forms of therapy in advanced prostatic carcinoma.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9241550     DOI： 10.1007/bf02551344

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  21 in total

1.  Decrease of serum testosterone by cyproterone acetate accompanied by an unexpected increase of calcitonin secretion capacity.

Authors:  H Mulder; D Eland; W H Hackeng; W Schopman
Journal:  J Urol       Date:  1987-08       Impact factor: 7.450

Review 2.  Complete androgen blockade for the treatment of prostate cancer.

Authors:  F Labrie; A Dupont; A Belanger
Journal:  Important Adv Oncol       Date:  1985

3.  Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.

Authors:  H J de Voogt; J G Klijn; U Studer; F Schröder; R Sylvester; M De Pauw
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

4.  Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.

Authors:  F Keuppens; L Denis; P Smith; A P Carvalho; D Newling; A Bond; R Sylvester; M De Pauw; K Vermeylen; P Ongena
Journal:  Cancer       Date:  1990-09-01       Impact factor: 6.860

5.  Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.

Authors:  N Bruchovsky; S L Goldenberg; K Akakura; P S Rennie
Journal:  Cancer       Date:  1993-09-01       Impact factor: 6.860

6.  The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.

Authors:  J I Miller; F R Ahmann; G W Drach; S S Emerson; M R Bottaccini
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

7.  Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2.

Authors:  T Jørgensen; K J Tveter; L H Jørgensen
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

8.  Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.

Authors:  F H Schroeder; T M Lock; D R Chadha; F M Debruyne; H F Karthaus; F H de Jong; J G Klijn; A W Matroos; H J de Voogt
Journal:  J Urol       Date:  1987-05       Impact factor: 7.450

Review 9.  Use of cyproterone acetate in prostate cancer.

Authors:  S L Goldenberg; N Bruchovsky
Journal:  Urol Clin North Am       Date:  1991-02       Impact factor: 2.241

10.  Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.

Authors:  M Pavone-Macaluso; H J de Voogt; G Viggiano; E Barasolo; B Lardennois; M de Pauw; R Sylvester
Journal:  J Urol       Date:  1986-09       Impact factor: 7.450
View more
  3 in total

1.  ZIP9 Is a Druggable Determinant of Sex Differences in Melanoma.

Authors:  Cristina Aguirre-Portolés; Riley Payne; Aspen Trautz; J Kevin Foskett; Christopher A Natale; John T Seykora; Todd W Ridky
Journal:  Cancer Res       Date:  2021-10-27       Impact factor: 12.701

2.  Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5.

Authors:  Linjie Chen; Dennis W Wolff; Yan Xie; Ming-Fong Lin; Yaping Tu
Journal:  BMC Cancer       Date:  2017-03-07       Impact factor: 4.430

Review 3.  Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5.

Authors:  Xia Gan; Yonghong Liu; Xueni Wang
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.